{"id":"lucanix","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lucanix is an autologous dendritic cell vaccine engineered to present the PRAME (preferentially expressed antigen in melanoma) tumor-associated antigen to the patient's immune system. The vaccine is designed to stimulate CD8+ T-cell responses against PRAME-expressing cancer cells, thereby enhancing anti-tumor immunity. This approach aims to provide durable immunological memory and reduce recurrence risk in cancer patients.","oneSentence":"Lucanix is a dendritic cell-based cancer vaccine that activates the immune system to recognize and attack tumor cells expressing PRAME antigen.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:43.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (adjuvant setting)"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT00676507","phase":"PHASE3","title":"Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy","status":"COMPLETED","sponsor":"NovaRx Corporation","startDate":"2008-07","conditions":"Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB","enrollment":532},{"nctId":"NCT01058785","phase":"PHASE2","title":"Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"NovaRx Corporation","startDate":"2003-03","conditions":"Lung Neoplasm, Carcinoma, Bronchogenic","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["belagenpumatucel-L"],"phase":"phase_3","status":"active","brandName":"Lucanix™","genericName":"Lucanix™","companyName":"NovaRx Corporation","companyId":"novarx-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"Lucanix is a dendritic cell-based cancer vaccine that activates the immune system to recognize and attack tumor cells expressing PRAME antigen. Used for Melanoma (adjuvant setting), Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}